This paper is only available as a PDF. To read, Please Download here.
Abstract
This paper reviews several recent publications concerning the use of opioids to control cancer pain and highlights the wide variation in mean daily dose. Present methods of reporting do not provide an explanation for these widely different doses used. It is essential that we understand the circumstances in which high doses are required, as higher doses are associated with greater toxicity and higher cost. Several factors that may influence the dose of opioid required are discussed. It is suggested that reporting of cancer pain, patient population, pharmacological and nonpharmacological interventions, and toxicity be standardized to allow for rational guidelines to be established for opioid use in pain due to advanced cancer.
Keywords
References
- Use of the subcutaneous route for the administration of narcotics in patients with cancer pain.Cancer. 1988; 62: 407-411
- Treatment of pain and other symptoms in cancer patients: patterns in a North American and a South American hospital.J Pain Symptom Manage. 1990; 5: 78-92
- Treatment of severe cancer pain by low-dose continuous subcutaneous morphine.Pain. 1989; 36: 169-176
- Inpatient narcotic infusions for patients with cancer pain.J Palliat Care. 1990; 6: 51-59
- Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients.Ann Intern Med. 1988; 108: 554-557
- The Brompton mixture versus morphine solution given orally: effects on pain.Can Med Assoc J. 1979; 120: 435-438
- Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use.Can Med Assoc J. 1992; 146: 891-897
- A long-term survey of morphine in cancer pain patients.J Pain Symptom Manage. 1992; 7: 259-266
- Cancer pain therapy with portable pumps.in: Abstracts of the 7th World Congress on Pain of the International Association for the Study of Pain. IASP Publications, Seattle1993: 328
- Care of the dying. Nurs Times 1959.in: DuBonlay S. Cicely Saunders: The Founder of the Modern Hospice Movement. Hodder and Stoughton, Toronto1984
- Living with dying: the management of terminal disease. Oxford University Press, Oxford1983
- Strong narcotic analgesics.Clin Oncol. 1984; 3: 109-133
- Relief of pain.in: Saunders CM The management of terminal disease. Edward Arnold, London1978: 65-92
- CPS: Compendium des Produits et Spécialités Pharmaceutiques. CK Productions, Toronto1993 (Vingt-Huitième Edition)
- Gilman AG Rall TW Nies AS Taylor P 8th ed. Goodman and Gilman's The pharmacological basis of therapeutics. Pergamon, New York1990
- Drugs for Pain.in: Abramowicz Marc The Medical Letter. 38. The Medical Letter Inc, New Rochelle, NY1993: 1-6 (887)
- The pain manual: principles and issues in cancer pain management. Pegasus Healthcare International, Montreal1991: 44
- Opioid hyperexcitability: the application of alternate opioid therapy.Pain. 1993; 53: 353-355
- Molecular and cellular mechanisms in opioid tolerance.in: Basbaum AI Besson JM Towards a new pharmacotherapy of pain. Wiley and Sons, West Sussex, England1989: 137-156
- Tolerance: factors involved in changes in the dose-effect relationship with chronic drug exposure.in: Basbaum AI Besson JM Towards a new pharmacotherapy of pain. Wiley and Sons, West Sussex, England1989: 157-179
- Pharmacologic approaches to cancer pain.in: Foley KN Payne RM Current therapy of pain. BC Decker, Toronto1989: 328
- Morphine analgesic tolerance: its situation-specificity supports a Pavlovian conditioning model.Science. 1976; 193: 323-325
- Heroin “overdose” death: contribution of drug-associated environmental cues.Science. 1982; 216: 436-437
- Explicitly unpaired delivery of morphine and the test situation: extinction and retardation of tolerance to the suppressing effects of morphine on locomotor activity.Behav Neural Biol. 1982; 35: 231-241
- Cholecystokinin antianalgesia: safety cues abolish morphine analgesia.Science. 1992; 256: 830-833
- Assessment of pain.Clin Oncol. 1984; 3: 17-31
- Incidence and implications of alexithymia in chronic pain patients.J Nerv Ment Dis. 1985; 173: 246-248
- Deafferentation syndrome: medical treatment.in: Nashold BS Ovelmen-Levitt J Deafferentation pain syndromes: pathophysiology and treatment. Raven, New York1991: 331-339
- Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence.Pain. 1993; 52: 259-285
- Dose and temporal parameters of morphine-induced hyperalgesia in the domestic fowl.Physiol Behav. 1990; 47: 385-387
- Intrathecal high dose morphine produces hyperalgesia in the rat.Brain Res. 1981; 209: 491-495
- Pharmacology of allodynia in rats evoked by high dose intrathecal morphine.J Pharmacol Exp Ther. 1988; 244: 501-507
- Lancet. 1992; 340: 1045
- Paradoxical pain following high-dose spinal morphine.Pain. 1987; 4: S389
- Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.Pain. 1993; 55: 93-97
- Paradoxical pain.in: Abstracts of the 7th World Congress on Pain of the International Association for the Study of Pain. IASP Publications, Seattle1993: 16
Article info
Publication history
Accepted:
April 19,
1995
Identification
Copyright
© 1995 Published by Elsevier Inc.
